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Background: WWOX, encoding WW domain-containing oxidoreductase, spans FRA16D, the second most common
chromosomal fragile site frequently altered in cancers. It is therefore considered a tumor suppressor gene, but its
direct implication in cancerogenesis remains controversial.
Methods and results: By whole-exome sequencing, we identified a homozygous WWOX nonsense mutation,
p.Arg54*, in a girl from a consanguineous family with a severe syndrome of growth retardation, microcephaly,
epileptic seizures, retinopathy and early death, a phenotype highly similar to the abormalities reported in lde/lde
rats with a spontaneous functional null mutation of Wwox. As in rats, no tumors were observed in the patient or
heterozygous mutation carriers.
Conclusions: Our finding, a homozygous loss-of-function germline mutation in WWOX in a patient with a lethal
autosomal recessive syndrome, supports an alternative role of WWOX and indicates its importance for human viability.
Keywords: WWOX, Tumor suppressor gene, Microcephaly, Epilepsy, Retinal degeneration, Nonsense mutation,
Whole-exome sequencingBackground
WWOX has been extensively studied for its role in cancer
because it localizes to a common fragile site, FRA16D, a
genomic region susceptible to chromosomal rearrange-
ments [1]. Indeed, somatic homozygous WWOX deletions
are common in various malignancies. Early lethality in
mice with targeted Wwox ablation has largely prevented
studies on tumor susceptibility, although focal bone le-
sions were interpreted as early osteosarcomas. Spontan-
eous tumor incidence was elevated in heterozygous mice,
and exposure to chemical mutagens further promoted
tumor formation [2]. Some studies in mice with condi-
tional Wwox deletion, however, did not support the
categorization of WWOX as a primary tumor suppressor* Correspondence: hanno.bolz@uk-koeln.de
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article, unless otherwise stated.gene since no spontaneous neoplasms were observed
[3,4]. Recently, expression studies in mice and the pheno-
type of rats with homozygosity for a spontaneous loss-of-
function allele have drawn the attention to a possible role
of WWOX in the developing central nervous system, in-
cluding the retina [5-7].Methods
Patients
We have evaluated five members of a consanguineous
Egyptian family. Written informed consent was obtained
from the parents, and the study was approved by the in-
stitutional review board of the Ethics Committee of the
University Hospital of Cologne and by the Ethics Com-
mittee of the National Research Centre, Cairo.Genetic investigations
Genomic DNA of II:4 was subjected to whole-exome
sequencing, WES. Exome capture was performed usingntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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following manufacturer’s procedures (Agilent, Santa
Clara, CA, USA) and sequenced with Illumina paired
end sequencing (protocol v1.2). Briefly, DNA was
sheared by fragmentation (Covaris, Woburn, MA, USA)
and purified using Agencourt AMPure XP beads (Beckman
Coulter, Fullerton, CA, USA). Resulting fragments were
analysed using an Agilent 2100 Bioanalyzer. Fragment
ends were repaired and adaptors were ligated to the
fragments. The library was purified using Agencourt
AMPure XP beads and amplified by PCR before hybrid-
isation with biotinylated RNA baits. Bound genomic
DNA was purified with streptavidin coated magnetic
Dynabeads (Invitrogen, Carlsbad, CA, USA) and re-
amplified to include barcoding tags before pooling for
sequencing on an paired-end, 100 cycle run on an Illu-
mina HiSeq 2000 according to manufacturer’s proto-
cols. Exome analysis was completed in OGT’s exome
pipeline. Briefly, reads were aligned to the human gen-
ome reference sequence GRCh37 using bwa 0.6.2. [8].
Local realignment was performed around indels with
the Genome Analysis Toolkit (GATK v1.6) IndelRea-
ligner [9]. Optical and PCR duplicates were marked in
BAM files using Picard 1.83 (http://picard.sourceforge.net).Table 1 Comparison of clinical findings in patient II:4, in the
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hypoglycemia, hypocalcemia, hypotriglyceridemia, hypocholesterolemia, hyponatre
malignancies was not supported by other studies on Wwox-deficient mice (see DiscOriginal HiSeq base quality scores were recalibrated using
GATK TableRecalibration and variants called with GATK
UnifiedGenotyper. Indels and SNPs were hard-filtered ac-
cording to Broad Institute best-practice guidelines (http://
www.broadinstitute.org/gatk/guide/topic?name=best-
practices) to eliminate false positive calls. Variant annota-
tion was done with a modified version of ENSEMBL’s Vari-
ant Effect Predictor. 14,268,914 read pairs were generated
of which 98.96% aligned to the human reference sequence
[10]. 85% of sequenced bases were characterized as ‘on
bait’ or ‘near bait’. The sample was sequenced to a mean
target coverage of 33.4×, with 64% of bases sequenced
to a depth of 20× or more.
Results
We have evaluated five members of a consanguineous
Egyptian family (the healthy parents were 2nd-degree cous-
ins) with the index patient, II:4 (Table 1 and Figure 1A,B),
affected by a novel syndrome with neonatal growth re-
tardation, microcephaly, retinal dystrophy, severe psy-
chomotor delay and intractable epileptic seizures. She
was born at 38 weeks by cesarean section as 2nd twin
after an uncomplicated pregnancy. Birth weight of
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Figure 1 Clinical and genetic characterization of the consanguineous Egyptian family described herein. A Pedigree. II:1 is depicted in
grey because she likely had the same disorder as II:4 but was never seen by the investigators. M, mutant WWOX allele; WT, wildtype WWOX allele.
B Patient II:4 with microcephaly and facial dysmorphism (bitemporal narrowing, high forehead, epicanthic folds, broad base of nose, long philtrum).
C Sanger sequencing confirmed the homozygous WWOX mutation in exon 2, c.160G > T (p.Arg54*) in II:4 (upper panel). Middle: Heterozygosity as seen
in both parents and II:3, lower panel: Wildtype sequence in the healthy brother. D Scheme of the human WWOX gene (vertical bars: exons) and
cartoon of the WWOX protein with two WW domains and the short-chain alcohol dehydrogenase/reductase domain. The position of the human
mutation (red) and the position corresponding to the rat frameshift mutation (c.1110_1122del/p.Leu371Thrfs*41) are given.
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age weight was 4,200 g (-2.1 SD), length 53 cm (-2.3 SD)
and head circumference (OFC) 34 cm (-3.6 SD). At 12
months, her weight was 5,800 g (-3.6 SD), length 66 cm
(-2.9 SD) and OFC 39 cm (-4.6 SD). She had bitemporal
narrowing, a high forehead, blue sclerae, epicanthic folds,
anteverted nares, a long philtrum, a short neck, and
clenched hands. Convulsions started at the age of 2
months. At 12 months, seizures started as hemiconvul-
sions with abnormal eye and mouth movements. Myo-
clonic movements persisted. Seizures partially responded
to valproate and lamotrigine. Deep tendon reflexes of
upper and lower extremities and flexor plantar responses
were increased. II:4 did not acquire any developmental
milestones and never recognized her mother. There
were no vocalizations. EEG showed generalized epileptic
abnormalities with frequent bursts of sharp and slow
waves. Parents noticed lack of response to any visual
stimuli at the age of two months, and ophthalmologicalexamination revealed optic atrophy with abnormal ret-
inal pigmentation. Scotopic and photopic flash electro-
retinogram (ERG) showed moderately reduced response
indicating retinal dysfunction. Photopic flicker ERG re-
vealed markedly reduced responses. Visual evoked po-
tential (VEP) showed reduced wave amplitudes and great
implicit time delays. In summary, the ophthalmological
examination indicated major impairment of retinocortical
transmission indicative for delayed visual maturation, and
bilateral severe macular and optic nerve dysfunction.
Echocardiography and audiological evaluation were nor-
mal. Cranial MRI demonstrated supratentorial atrophy
with simplified gyral pattern, hypoplasia of the hippocam-
pus and the temporal lobe with consecutively widened
subarachnoidal space, and a thin hypoplastic corpus callo-
sum. Chromosomal examination from peripheral blood
lymphocytes revealed a normal female karyotype, 46,XX.
Normal results were found in metabolic screening includ-
ing liver and renal function tests, complete blood count,
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urea, electrolytes, urine and serum amino and organic
acids, and very long chain fatty acids. II:4 died at the age
of 16 months because of status epilepticus. No autopsy
was performed.
The 1st twin of II:4, II:3, was a healthy girl. The older
sister of II:4, patient II:1, deceased at 3 months of age
with similar symptoms, probably affected by the same,
presumably recessive disorder. Patient II:1 died several
years ago and has not been seen by the authors because
the family was only referred to genetic counseling after
II:4 had been born with similar symptoms. II:1 was born
as first child at 39 weeks of gestation by spontaneous va-
ginal delivery after an uncomplicated pregnancy. The
father and mother were 22 and 26 years old then, re-
spectively. Records on neonatal growth parameters were
not available. Seizures started at the age of 40 days as
generalized tonic-clonic fits that could partially be con-
troled by valproate and lamotrigine. At 2 months of age,
the parents noticed that she was not following objects
and did not react to light. No detailed ophthalmological
investigations or brain imaging were done. At 3 months,
she was admitted to hospital because of heavy convul-
sions and died one week later during sleep. Autopsy was
not performed. There were no additional individuals in
the family with symptoms comparable to those of II:1
and II:4. There was no history of cancer, not even in the
older generations.
WES identified 41,639 SNPs and indel variant posi-
tions, of which 2,597 had not been previously identified
in dbSNP release 132. 495 of these were non-
synonymous. To reduce the search space for causative
mutations, the 41,693 variants were filtered stringently,
removing variants that had been seen in OGT’s private
database in 30% or more of previously analysed samples.
Variants were also removed if they were present in
dbSNP release 137 or had been identified as part of the
1000 Genomes project. After this filtering 639 variants
(of all consequences) remained. Reducing variants to
only exonic regions left 523 novel variants. Assuming
that the disease-causing mutation locates in a region of
homozygosity by descent (HBD) [11], variants were fil-
tered for homozygous positions. Considering only those
variants with a “serious” tag in the OGT pipeline (affect-
ing essential splice sites; frameshifts in coding sequence;
gained or lost stop codons; non-synonymous coding var-
iants; complex insertions/deletions) further reduced
them to 15 (Table 2). LOH (loss of heterozygosity) re-
gions, probably reflecting HBD segments resulting from
parental consanguinity, were identified by analysing the
regions surrounding candidate variants in the VCF file,
excluding sites with low coverage, known polymorphic
genes and potentially mis-genotyped homopolymer
indels to define the region sizes presented in Table 2.Only five variants were predicted as deleterious by all or
most programs and localized to LOH regions, including
a gained stop codon in WWOX (WW domain containing
oxidoreductase) that localizes in exon 2 and affects
codon 54 for arginine (c.160G > T; p.Arg54*) in the lar-
gest LOH region identified (54 Mb) (chr16:25,457,305-
79,894,309; GRCh37) [Additional file 1: Figure S1]. It is
homozygous for SNPs with the exception of PDPR, a
gene exhibiting common copy-number polymorphism.
Sanger sequencing confirmed the homozygous WWOX
mutation in II:4, and both parents and the healthy twin
sister (II:3) were heterozygous carriers. The healthy
brother (II:2) was homozygous for the wildtype allele
(Figure 1C). There are no variants at this position
(c.160) of WWOX in the Exome Variant Server database.
There are some rare missense variants (with minor allele
frequencies <1%), but only two other stop gain muta-
tions, c.214C > T (p.Gln72*; rs201008667) and c.749C >
G (p.Ser250*; rs368928190). A gained stop codon in
POMC (proopiomelanocortin) had been sequenced at
very low depth (3×) in WES and turned out heterozy-
gous by Sanger sequencing.
Discussion
Many genes have been assigned roles in tumorigenesis
at the time of their discovery based on expression stud-
ies, somatic alterations in tumor cells or both. For ex-
ample, FUS (fused in sarcoma) was initially classified as
a fusion oncogene in human myxoid liposarcomas [12],
and later implicated in Mendelian neurodegeneration
through the identification of germline mutations in fa-
milial amyotrophic lateral sclerosis [13]. Another ex-
ample is the unexpected identification of germline
mutations in members of the Ras signaling pathway in
different monogenic syndromes, including a neurodeve-
lopmental disorder, Costello syndrome [14]. Similarly,
we have identified a homozygous truncating germline
mutation in WWOX, a gene so far considered a tumor
suppressor gene, in a severe recessive neurodevelopmen-
tal syndrome.
The implication of WWOX in a monogenic disorder
may appear unexpected. However, the probability of
WWOX being a recessive disease gene ranked very high
(31) in an estimation for 14,142 genes [15]. This is com-
patible with only two other stop gain mutations of very
low frequency, p.Gln72* (MAF 0.016%) and p.Ser250*
(MAF 0.008%), listed in the Exome Variant Server data-
base, likely representing rare pathogenic recessive alleles.
Moreover, there is considerable overlap of symptoms in
our patients with those observed in Wwox murine
models (Table 1): A spontaneous homozygous Wwox
frameshift mutation (p.Leu371Thrfs*41) resulting in
non-detectable protein underlies lethal dwarfism and
epilepsy (lde) in lde/lde rats, suggesting an important















IMPG2 3 100995556 13 c. 535 T > G p. Ser179Ala (intronic
in most transcripts!)
tol tol tol tol Recessive retinitis, ar n.d. 20
PHACTR1 6 12749777 4 delC - n.a. n.a. n.a. no n.d. no
TAS2R38 7 141672688 34 c. 802C > T p. Pro268Ser tol delet delet tol no n.d. 2.2
ERMP1 9 5832849 3 c. 179C > T p. Ala60Val tol tol tol tol no n.d. 3
MRRF 9 125033286 112 c. 116A > G p. His39Arg tol tol tol tol no n.d. 2.7
GLE1 9 131302562 18 c. 1211C > T p. Ala404Val tol delet delet delet Lethal arthrogryposis
with anterior horn cell
disease, ar
n.d. 3.7
HCFC2 12 104461873 60 c. 461A > T p. Asn154Ile delet delet delet delet no n.d. 3.3
RBM19 12 114261045 18 c. 2867A > C p. Gln956Pro delet tol tol tol no n.d. 3.6
SPTBN5 15 42174192 8 c. 2392_2393ins p. Glu800Glyfs*41 n.a. n.a. n.a. delet no; LoF-tolerant gene! no no
DUS2L 16 68107968 14 c. 842C > G p. Thr281Ser tol tol tol delet no n.d. 38
AP1G1 16 71784192 70 c. 1328A > T p. Gln443Leu tol tol tol delet no n.d. 1.8
ZFHX3 16 72821594 76 c. 10804_10812del p. Ala3602_Ala3604del n.a. n.a. n.a. tol no n.d. 8.6
WWOX 16 78142372 12 c. 160G > T p. Arg54* n.a. n.a. n.a. delet no yes 54
ABCG1 21 43680243 3 c. 718G > A p. Glu240Lys tol tol tol tol no n.d. no
Variants in TAS2R38, GLE1, HCFC2, ZFHX3 and WWOX represented prime candidate variants because they localized within an LOH region and were predicted as pathogenic by most programs. Note that the POMC
nonsense mutation was covered only 3 times, and Sanger sequencing revealed that it was in fact heterozygous which is compatible with POMC not localizing in an LOH region. The SPTBN5 frameshift mutation was
found to be homozygous in II:4 and her healthy twin. SPTBN5 has been described as a non-essential gene that tolerates loss-of-function variants (LoF-tolerant) [15]. ar, autosomal recessive; n.a., not applicable:
Assessment of deletions or insertions is out of scope for the methods of the prediction programs which require knowledge of the ancestral amino acids at that position (except Mutation Taster); delet, predicted as
deleterious; tol, predicted as being tolerated; n.d., not defined: Segregation analysis was not carried out; LOH region: If a variant is embedded in a run of homozygous SNPs, indicating a loss of heterozygosity region,
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vous system [7]. lde/lde rats display vacuoles in the
hippocampus, a brain region that appeared dysplastic in
the MRI of patient II:4 (Figure 2A). Like patient II:4 and
lde/lde rats, knockout mice show growth retardation
and die early, but no seizures were observed.
Wwox is highly expressed in different brain regions
during murine fetal development. Whilst mostly de-
creasing after birth it remained unchanged in the cortex
and the corpus callosum in adult mice [6] – which fits
the observation of cortical atrophy and hypoplasia of the
corpus callosum in our patients. The intractable epilep-
tic seizures observed in the human family and in the rat
model will at least in part result from these anatomical
brain abnormalities, but considering the putative role of
WWOX as a signaling protein [16], disruption of neur-
onal pathways may additionally increase the susceptibil-
ity for seizures.
Severe retinal degeneration and optic atrophy were
present in II:4 and probably in II:1, too, and compatible
with early infantile retinitis pigmentosa, RP. Interest-
ingly, Wwox is moderately to highly expressed in the
murine developing retina [6] and overexpressed in the
inner and outer nuclear layers after light-induced dam-
age [5]. It colocalizes with opsin-positive cones and was
enriched in damaged mitochondria and condensed nuclei
of degenerating photoreceptors [5]. Intriguingly, Wwox
was upregulated with age in retinae of rd mice with muta-
tions in Pde6b, a recessive RP gene in humans [17]. In
monogenic forms of optic atrophy, the disease primarily af-
fects the retinal ganglion cells (RGCs) [18]. The specific ex-
pression of Wwox in RGCs, its colocalization with Brn3b
[6], a protein that is crucial for RGC axon outgrowth [19],A B
Figure 2 Brain MRIs of II:4. A Supratentorial atrophy with thin cerebral co
in the coronal plane. B Hypoplasia of corpus callosum. Note craniofacial dy
temporal lobes with widened subarachnoidal space (blue arrow), hippocamand continued expression in the optic tract in adulthood
could explain the optic atrophy in our patients.
By interaction with many proteins via its WW and
SDR domains, WWOX is thought to act in various sig-
naling pathways [2,16]. In WWOX deficiency, disease in
the central nervous system may result from disruption
of some of these interactions, e.g. with dishevelled seg-
ment polarity protein 2 (DVL2) and Tau, proteins in-
volved in cortical development and neurodegeneration
[2]. The severe dwarfism in Wwox-/- mice has been at-
tributed to delayed bone formation resulting from dys-
regulation of RUNX2, a WWOX-controlled regulator of
skeletal morphogenesis, and to down-regulation of genes
for nucleosome assembly and cell growth [20].
Metabolic disease has been reported in Wwox-deficient
mice (see legend for Table 1), but was not evident during
her short life in patient II:4. Spontaneous tumor incidence
was moderately elevated in heterozygous Wwox knockout
mice compared to wildtype, and exposure to chemical
mutagens dramatically promoted tumor formation [21].
However, some mouse studies raised doubts on the gene’s
role as a classical tumor suppressor [3,4,20-22], and nei-
ther the rat model nor members from the human family
reported here displayed a tendency to develop tumors. It
is possible that tumors would have developed later in life
in II:1 and II:4 if the condition would have been compat-
ible with a longer survival. No tumors have developed so
far in the heterozygous carriers in our family, and there
was no history for cancer in the extended family (with
possibly several carriers of the mutation). However, an in-
creased cumulative lifetime risk, especially if exposed to
carcinogenic agents, seems conceivable and should result
in regular preventive medical checkups.C
rtex (yellow arrow) and hippocampal dysplasia (red arrow) are visible
sproportion and sloping forehead (sagittal MRI). C Hypotrophic
pal malformation (red arrow) and gyral pattern anomaly (axial MRI).
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Our findings – albeit based on the presumption that the
causative mutation in this consanguineous family will be
homozygous (we can not exclude disease-causing com-
pound heterozygosity in a gene outside the HBD re-
gions) – suggest a redefinition of WWOX as a protein
that has entirely different functions in the germline ver-
sus the soma. It joins the ranks of other tumor suppres-
sor genes that have been recognized to be crucial for
neurodevelopment when mutated in the germline.
Additional file
Additional file 1: Figure S1. Schematic representation of the mapped
sequencing reads covering the WWOX mutation in patient II:4 (visualized
with the Integrative Genomics Viewer, IGV).
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